GlassScriptPhysician profile
Melissa A Haas
NPI 1144894429
$1,895.31
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.00 · 2022: $1,545 · 2023: $328.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $328.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $327.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.22 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $288.11 | 2022 | |
| Novo Nordisk INC | $266.06 | 2022-2023 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $232.00 | 2022-2023 | |
| Glaxosmithkline, LLC. | $95.59 | 2022-2023 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $94.72 | 2022-2023 | Spravato |
| Otsuka America Pharmaceutical, INC. | $71.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.34 | 2022 | |
| Global Blood Therapeutics, INC. | $54.36 | 2022 | |
| Merck Sharp & Dohme LLC | $54.16 | 2022 | |
| Amarin Pharma, INC. | $49.96 | 2022 | |
| Sunovion Pharmaceuticals INC. | $45.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $41.88 | 2022 | |
| Pfizer INC. | $39.63 | 2022-2023 | |
| Genentech USA, INC. | $22.00 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $21.48 | 2023 | |
| Amgen INC. | $20.96 | 2023 | Prolia |
| Astellas Pharma US INC | $20.13 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $19.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.27 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.86 | 2022 | |
| Lilly USA, LLC | $11.98 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Haas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.